Drug Approval | November 30, 2022
CPHI & PMEC India 2022 showcases array of machinery, ingredients and technology
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
The Business Undertaking of Watson is engaged in the business of developing, manufacturing, marketing and sale of API.
Through lifestyle modifications, ADORE will assess the progress of patients based on parameters like reduction in blood sugar levels and weight, among others
The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India
Approval broadens indication for ENHERTU to earlier use in metastatic breast cancer and requirement for confirmatory phase 3 trial
Total investment envisaged in this project stands at up to Rs 70 crore
The two have agreed to jointly undertake R&D activities on scientific validation of Ayush concepts, procedures and products
It serves to leverage the strengths of various institutions to coordinate AMR surveillance lab networks
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Subscribe To Our Newsletter & Stay Updated
